Mechanisms vs Demonstrated Clinical Benefits

Three different kinds of statement

Peptide writing mixes three kinds of statement that look alike.

1. Mechanism: "It activates this receptor" or "it raises this signal."
2. Biomarker or surrogate: a measurement such as a hormone level, a blood test or an imaging result.
3. Clinical outcome: whether people feel better, function better or live longer.

FDA explains the difference: clinical outcomes directly measure whether people in a trial feel or function better, or live longer, while a surrogate endpoint is a substitute used for the outcome. A surrogate can be accepted only after extensive evidence shows it predicts clinical benefit in a particular context. [1] A review of the FDA-NIH biomarker framework (BEST) likewise separates biomarkers from clinical outcome assessments. [2]

Evidence labels used on this page

Approved medicine (a regulator has approved it for a stated use), promising but limited, insufficient evidence, preclinical (cells or animals only), marketing claim. A study that measures only a marker does not earn a clinical-benefit label.

Example 1: a growth-hormone marker study (MK-677)

MK-677 (ibutamoren) is described in the trial as an oral ghrelin mimetic. The library explains why it is not classed as a peptide in MK-677 is not a peptide. In a 2-year randomized trial of 65 healthy adults aged 60 to 81, it raised growth hormone and IGF-I to the levels of healthy young adults, and fat-free mass rose over 12 months (change of 1.1 kg versus a fall of 0.5 kg with placebo). The authors noted the study was too small and too short to evaluate functional outcomes. [3] The numbers moved in the expected direction, but whether anyone could do more, fall less or live better was not tested. The label for this evidence is biomarker change with limited clinical outcome data.

Example 2: a long-acting growth-hormone-releasing analogue (CJC-1295)

In 2006, two randomized placebo-controlled trials in healthy adults (aged 21 to 61) reported that CJC-1295 raised mean GH levels by 2- to 10-fold for 6 days or more and IGF-I by 1.5- to 3-fold for 9 to 11 days, with no serious adverse reactions reported. [4] The main outcome measures were GH, IGF-I and pharmacokinetics. [4] It is a pharmacology study in healthy people. It did not test muscle, recovery or aging, so any such claim is a marketing claim on this evidence. Higher GH or IGF-1 is not inherently better. A small trial with no serious reactions does not establish safety. See biomarker changes vs meaningful health outcomes and growth-hormone-releasing peptides.

Example 3: BPC-157 and tissue repair

A 2025 systematic review of BPC-157 in orthopedic sports medicine included 36 studies, 35 of them preclinical and 1 clinical. In animal models it improved muscle, tendon, ligament and bone outcomes and acted through several growth and blood-vessel pathways. The review found no clinical safety data. [5] A 2026 systematic review looking only for human studies found three (30 participants in total), judged them poor in quality, rated overall certainty as very low and concluded it should not be used clinically outside regulated, high-quality trials. [6]

So the mechanism story is rich, the animal results are many, and the human evidence is insufficient evidence for any of these uses. Animal and cell results should not be carried over to people. See BPC-157 and tissue repair models and their limits.

Contrast: when the chain is complete

The semaglutide label describes a mechanism (activating the GLP-1 receptor, stimulating insulin and lowering glucagon in a glucose-dependent way), and the medicine has a regulator-reviewed label. [7] The point is not that mechanisms are weak. FDA says clinical trials are what show a new product delivers a positive balance of benefit and risk. [1] The other examples on this page lack that step.

Questions to ask of any claim

• Is the result from cells, animals or people?
• Which exact molecule and product were tested; is it what is sold?
• Is the outcome a marker or something a person would notice?
• How many people, for how long, compared with what?
• Who ran and paid for it, and has it been repeated?
• What adverse events were recorded, and for how long?

Use these questions to read claims, not to decide on treatment. Questions about a medicine belong with a clinician; see talking with a health professional and how to evaluate peptide claims.